Provention Bio


Research-driven biopharmaceutical company engaged in discovery, development and large-scale manufacturing of medicines and vaccines. Operates domestic biologics and vaccine production facilities, maintains serialization and supply-chain traceability systems, provides patient access and support programs, and publishes patient- and community-focused content to support disease awareness, screening and advocacy.

Industries

N/A

Nr. of Employees

medium (51-250)


Patents

Methods for treating type 1 diabetes

US-12565529-B2

View Details

Methods and compositions for preventing type 1 diabetes

US-12006366-B2

View Details

Methods and compositions for preventing type 1 diabetes

US-11434291-B2

View Details

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

US-9056906-B2

View Details

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

US-8663634-B2

View Details

Products

Prescription medicines (multiple therapeutic areas)

A portfolio of prescription medicines across therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, cardiovascular disease, diabetes and transplant.

Vaccines and immunization products

Vaccine products and immunization solutions intended to protect population health across life stages and for emerging epidemics.


Services

Programs to reduce out-of-pocket costs, provide copay assistance and supply free medicine to eligible patients; includes a centralized patient support navigation service.

Evidence-based product information and adverse-event reporting support for healthcare professionals.

Provision of lot- and serial-level traceability data via portal access, EPCIS feeds, and verification services to authorized trading partners.

Expertise Areas

  • Vaccine development and manufacturing
  • Large-scale biologics production
  • AI-enabled research and manufacturing optimization
  • Clinical trial design with community engagement
  • Show More (7)

Key Technologies

  • mRNA platform development
  • Recombinant biologics manufacturing
  • Vaccine formulation and sterile filling
  • Mass spectrometry
  • Show More (8)

News & Updates

Management reviewed Q2 2026 financial results in a live audio webcast followed by Q&A on July 30, 2026.

U.S. approval announced for a therapy described as disease-modifying for patients recently diagnosed with stage 3 type 1 diabetes.

Announcement of U.S. approval for a subcutaneous anticancer treatment administered via an on-body injector device.

Company announced it would not submit a specified therapy for global regulatory reviews.

Article exploring a telehealth-enabled platform designed to request type 1 diabetes screening.

Patient-centered story about how risk for type 1 diabetes affects a family.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.